HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Stoke Therapeutics (NASDAQ:STOK) and maintained a $35 price target.
June 08, 2023 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Stoke Therapeutics and maintained a $35 price target.
The reiteration of a Buy rating and maintenance of a $35 price target by HC Wainwright & Co. analyst Andrew Fein indicates a positive outlook for Stoke Therapeutics. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100